Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer.
Saved in:
| Title: | Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. |
|---|---|
| Authors: | Perez K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Chiarella AM; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Horick N; Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA., Weekes C; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Abrams T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Blaszkowsky L; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Enzinger P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Giannakis M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Goyal L; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Meyerhardt JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Rubinson D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Goessling W; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Giantonio BJ; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Brais L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Germon V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stonely D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Bakir B; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Das K; Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA., Pitarresi JR; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Needle M; AVEO Oncology, Cambridge, MA, USA., Rustgi AK; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA. |
| Source: | The oncologist [Oncologist] 2023 May 08; Vol. 28 (5), pp. 425-432. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyad002 |
